Evaluation of maintenance treatment with PARP inhibitors in ovarian carcinoma patients responding to platinum therapy: Use of restricted mean survival time as an index of efficacy
CONCLUSION: Maintenance therapy studies provide evidence that olaparib, niraparib, rucaparib are effective treatments for advanced ovarian cancer.PMID:34779394 | DOI:10.5414/CP204113
Source: International Journal of Clinical Pharmacology and Therapeutics - Category: Drugs & Pharmacology Authors: Luca Cancanelli Daniele Mengato Lorenzo Di Spazio Melania Rivano Marco Chiumente Andrea Messori Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Drugs & Pharmacology | Men | Ovarian Cancer | Ovaries | Study